



LKT Laboratories, Inc.

**SB-202190**

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)

Web: [lktlabs.com](http://lktlabs.com)

## Product Information

**Product ID** S041001

**CAS No.** 152121-30-7

**Chemical Name** 4-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol

**Synonym** SB202190; SB 202190; FHPI; UNII-PVX798P8GI ; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole

**Formula** C<sub>20</sub>H<sub>14</sub>FN<sub>3</sub>O

**Formula Wt.** 331.35

**Melting Point**


**Purity** ≥99%

**Solubility** Soluble in DMSO to 100 mM,  
20mg/mL in ethanol,  
2mg/mL in Ethyl acetate

**Store Temp**

**Ship Temp** Ambient

**Description** SB-202190 is a highly selective p38 MAPK inhibitor. In a rabbit model, treatment with SB-202190 after filtering glaucoma surgery improved bleb characteristics and intraocular pressure. In a chronic hypoperfusion rat model of vascular dementia, treatment with SB-202190 reduced apoptosis of hippocampal neurons and rescued spatial learning and memory deficits.



**Bulk quantities available upon request**

Product ID	Size
S041001	5 mg
S041001	25 mg
S041001	100 mg

**References** Nassar K, Tura A, Luke J, et al. A p38 MAPK inhibitor improves outcome after glaucoma filtration surgery. J Glaucoma. 2015 Feb;24(2):165-178. PMID: 25493622.

Yang S, Zhou G, Liu H, et al. Protective effects of p38 MAPK inhibitor SB202190 against hippocampal apoptosis and spatial learning and memory deficits in a rat model of vascular dementia. Biomed Res Int. 2013;2013:215798. PMID: 24455679.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.